AKBA vs VRTX: Which Stock is Better?
Side-by-side comparison of Akebia Therapeutics Inc and Vertex Pharmaceuticals Inc in 2026
AKBA
Akebia Therapeutics Inc
$1.55
VRTX
Vertex Pharmaceuticals Inc
$441.70
Key Metrics Comparison
| Metric | AKBA | VRTX | Winner |
|---|---|---|---|
| Market Cap | $417.89M | $113.01B | VRTX |
| P/E Ratio | N/A | 28.98 | VRTX |
| EPS (TTM) | $N/A | $15.33 | VRTX |
| Revenue Growth | 0.2% | 0.1% | AKBA |
| Gross Margin | 82.9% | 53.7% | AKBA |
Analyze AKBA
Full quant analysis
Analyze VRTX
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is AKBA or VRTX a better investment?
Comparing AKBA and VRTX: Akebia Therapeutics Inc has a market cap of $417.89M while Vertex Pharmaceuticals Inc has $113.01B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between AKBA and VRTX?
AKBA (Akebia Therapeutics Inc) and VRTX (Vertex Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: AKBA or VRTX?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: AKBA or VRTX?
AKBA has higher revenue growth at 0.2% vs 0.1% for VRTX.
Which company is more profitable: AKBA or VRTX?
Akebia Therapeutics Inc (AKBA) has higher gross margins at 82.9% compared to 53.7% for VRTX.
Which is the larger company: AKBA or VRTX?
Vertex Pharmaceuticals Inc (VRTX) is larger with a market cap of $113.01B compared to $417.89M for AKBA.
Should I buy AKBA or VRTX in 2026?
Both AKBA and VRTX have investment merit. AKBA trades at $1.55 while VRTX trades at $441.70. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between AKBA and VRTX stock?
Key differences: Market Cap ($417.89M vs $113.01B), P/E Ratio (N/A vs 29.0x), Revenue Growth (0.2% vs 0.1%), Gross Margin (82.9% vs 53.7%).